According to the pr, it’s in Guerrero, Mexico

Thank you and looking forward to seeing this unfold.

This has nice potential. Looking for some sort of pr soon for some sort of confirmation.

You being a mod, is that dd worth a sticky note?

Exactly. Frank Igwealor being announced cfo in the 8k and also cfo of Cannabinoid Sciences has to be related. Also factor in the matching addresses and this could fly.

Doing some dd here. Frank Igwealor is new CFO according to the 8k. I found this pr about Cannibinoid Sciences. It was posted 2 days ago. They are acquiring CBD companies that are profitable. The most interesting thing is that the address on the pr and the address on the 8k match. Notice projected revenue also. Could these acquisitions umbrella under one company? Lots of coincidences here. https://www.prweb.com/releases/cannabinoid_biosciences_inc_has_executed_five_game_changing_non_binding_letter_of_intent_loi_with_five_cbd_operations_across_the_united_states_of_america/prweb16814456.htm

I agree it’s still undervalued but I must admit it’s a little disappointing watching the os going from 18 million to 100 million. This dilution must be happening for expansion purposes as I would think the notes are now paid. That said, I’m still holding my shares but I also hope the os doesn’t get out of control.

Spoke too soon. 2,174,900 at .0182. This needs to stop or they are going to kill this stock.

There is definitely dilution. There was another 3.4 million share t-trade today. This probably puts OS around 75 million now. We will have difficulty moving up as long as the dilution is happening. That said, I would think notes are close to being paid off. As long as OS is relatively small we should move up once dilution is over as current market cap is much lower than it should be. We just need dilution to stop soon without getting out of hand.

Wow! Ballsy! I could understand buying early a.m. Friday. Was expecting a price drop then but it’s almost at an all time low. That said, you have a decent chance of more decline Monday but cold will be sweeping much of the nation next week. I would expect a bigger draw on next week’s report and some covering possibly as early as a Tuesday or even Monday afternoon. Good luck!

Thanks for the information. Good stuff. Out if curiosity where did you find that info?

Although Curaleaf is expanding at a greater pace than Trulieve, Trulieve is also expanding but in a much different way. Breaking it down:

First, let’s look at the OS. As of June 30th, Trulieve had an OS of 110,132,168 and, on July 25, they had 10.3 million shares unlock and personally I think this is the main reason for the recent pps decline. On January 25, 2020 they will have another 11,205,960 shares unlock and on July 25, 2020 the remainder of the 54,047,133 shares will unlock.

Now Curaleaf...as of June 30th, they had an OS of 351,052,287 and fully diluted shares totaling 461.3 million. They will also issue another 95,556,556 shares upon completion of the acquisition of Cura Partners and they will issue another 102,808,038 shares upon completion of the acquisition of Grassroots. Also, on October 20, 2019 Curaleaf is going to unlock approximately 55 million shares and then another 55 million the following quarter until they ultimately reach 371,208,255. That’s a lot of shares unlocking.

Second, just yesterday Schall law firm filed a class action suit against Curaleaf. To be fair though, Kim Rivers husband, J.T. Burnette is being indicted in connection with public corruption. Though neither Kim or Trulieve has been indicted it is still bad pub.

Third, let’s look at expansion. Trulieve’s Massachusetts cultivation facility will be online in q1 2020 and will start producing Trulieve’s revenue for the first time out of the state of Florida. Trulieve bought Life Essence in November. It has plans for both medical marijuana dispensaries and recreational marijuana shops in Holyoke, Northampton and Cambridge, along with the growing and packaging operation in Holyoke

Also, as stated in their last conference call, they own 80% of the California based “Leef Industries” and stated they anticipate completing the acquisition within the next few weeks.

They also recently acquired “The Healing Corner” which is a medical marijuana facility in Bristol, Connecticut and we know they have been lobbying in Georgia and in relation to that we know this was said, “Compass is near finalizing a deal with a “major partner” to pursue medical marijuana business in Georgia.” So we don’t know exactly what is happening here but it’s a good bet that Trulieve May be entering the market in Georgia as well.

I won’t go into as much detail with Curaleaf but they will be the largest cannibis company once its acquisitions of Grassroots and Cura Partners are complete. They will be operating in 19 states. No questioning they will undergo massive growth. What’s interesting is the different approaches between the two.

Curaleaf is expanding by a combination of dilution and cash where Trulieve is doing it mostly without dilution. This, in my opinion, will help preserve share value. So as of now, Curaleaf will have to be 5x the market cap of Trulieve to have an equal share price. Also, Curaleaf will have 371 million shares unlocking as opposed to 65 million shares Trulieve shares unlocking.

Lastly, let’s look at earnings. Trulieve reported $57.9 million in quarterly revenue with $37.6 million gross margin and an adjusted EBITDA of $31.6 million with $0.52 income per share. 2019 projections revenue projections are $220-$240 million with an EBITDA of $95-$105 million. 2020 revenue projects to be $380-$400 million.

Curaleaf reported managed quarterly revenue of $55.1 million and pro forma revenue of $110.9 million and an EBZITDA of $3.36 million. However, they also reported a net loss of $25.54 million or $.05 a share. Curaleaf does project $1 billion in revenue for 2020.

In summary, Curaleaf is growing at a faster pace than Trulieve but their share count is also much higher than Trulieve’s. Looking at 2020 estimates, Curaleaf is projected to bring in 2 to 3 times the revenue of Trulieve so theoretically they should be 2 to 3 times the market cap of Trulieve. That said though, they are currently operating at a loss where Trulieve is currently profitable. But take that aspect out and just assume Curaleaf market cap is 3 times greater than that of Trulieve, based on the OS Trulieve share price should still be at least 50% higher than Curaleaf’s. Also, factor in that Curaleaf is going to have 371 million shares unlocking compared to 64 million for Trulieve. Now factor in the potential that Florida legalized Recreational mj and it just seems to me Trulieve currently has more potential. Case in point, look at Aurora. They are one of the biggest mj companies in the world with a market cap of $5.66 billion but also have an OS of over a billion and share price is only $5.55. Ultimately both Curaleaf and Trulieve should be long-term winners.

I have been following the sector closely for almost two years now and Trulieve continues to impress the most. Truthfully we have a perfect storm for a buying opportunity right now. I’m sure many Trulieve investors aren’t happy with recent price action but personally I’m really happy with it because it presents optimal buying opportunities.

My take on all of this is that currently the market cap is $892.3 million which is less than 4x 2019 revenue projections of roughly $250 million and just over 2x 2020 revenue projections of $400 million. Furthermore they have a very strong balance sheet and an os of roughly 110 million and they are growing leaps and bounds. Next year there is also a strong possibility that Florida legalized rec mj. Also the election is next year and legal mj is sure to be a hot topic like. And, lastly they are expanding to other states too.

The combination of bad market sentiment, the trade war and the share unlock has presented a once in a lifetime buying opportunity that will probably never be seen again.

I have accumulated 5,700 shares and intend to add Monday as well. By the time next year I fully expect Trulieve to be, at the very least, a $20 stock and I think that’s conservative. They are are a strong growth companies and the most profitable in the sector with so many catalysts on the horizon. I can only imagine how much 5,700 shares will be worth in five years.

Agreed and well stated.

They should get benefits from the 500% increase in production capacity.

Q2 numbers should be impressive when they report pre-market on August 14th imo. When buying Charlotte’s Web last quarter the most sought after product was their maximum strength oil. It was also the most difficult to find as you couldn’t buy it online and the stores I bought from would generally sell out of the maximum strength within a couple of days.

I suspect that the reason it wasn’t available online was because they had maximized the extraction yield from their 2017 harvest. I also think that this was the reason for their flat q1 revenue numbers.

Charlotte’s Web went on to report that March was a record sales month. This is probably because the extraction yield from the massive 2018 harvest started to hit the market. I also think that this is also why the maximum strength oil became available online. It should also be noted that Charlotte’s Web stated in the q1 report that their revenue guidance of $120-$170 million remained in tact. I think it was because they knew the demand was high.

If indeed the q1 numbers were a result of the maximized extraction yield , that won’t be a problem for the q2 numbers. I wouldn’t be surprised if revenue hits $30 million for q2 and I also wouldn’t be surprised if they raise their 2018 revenue estimates in lieu of the Kroger deal depending upon how quickly Kroger’s get their products on the shelf.

I am locked and loaded with shares and anticipate sone very nice q2 numbers and new all-time pps highs within a month. Charlotte’s Web appears to have a very bright future.

I’ve been watching this board for awhile and it’s funny how it went from excitement to hope to skepticism to just flat out fraud. Anyway, the reality is that no one really knows what’s going on but the most likely scenario is that the financials simply aren’t ready.

Yes, it’s disappointing and everyone has a right to be angry about watching their investment dwindle but honestly I’m hoping to score some .02s tomorrow. At this point in the game I truly think the reward outweighs the risk as I think they will be filing soon.

Just my opinion and I could be totally wrong but I will take that risk at this point.

Personally I have 36,000 shares I bought at .0671 and I will add some more tomorrow if I am fortunate enough to be able to score some .04s that were being bought yesterday. I think we will see the filing very soon which should send the price skyrocketing. I think it’s well worth the investment risk at this time.

It probably is unless they file.

Exactly. If this was a scam we would see prs etc. to boost share price. I do agree that it’s not good that they haven’t met the filing deadline but I suppose it’s understandable with switching accounting firms.

I do imagine that they will file (hopefully today) and when they do, depending on the content, this could skyrocket based on information in previous prs and what share price has been.

I have been watching this closely but didn’t buy in until yesterday at .0651. Now it definitely feels like the risk/reward is worth it at these prices. I guess we will see.

Long-term the total sales will hold merit but short-term (the next 3 to 4 months) sales are irrelevant as Vyleesi won’t even go on market until September. In the meantime they will get $60 million dollars and probably a very nice earnings report in September. Some analysts are saying 6 cents a share which would be a 650% growth yoy.

Going back to sales their first royalty payment would be $25 million on $250 million Vyleesi sales. That number is a moderate number and very doable even if sales are just mediocre. Regardless they won’t have to spend any money on marketing so they only stand to gain money which could be up to $300 million total in royalties.

Now let’s throw in the fact that they also have other drugs in clinical trials and two more in phase 1 and a market cap of $215 million. Also, factor in that 9 form 4s were filed today indicating a nice amount of insider buying by 9 individuals.

Sure the stock took a hit but it would be my guess that we could double or triple from here after their financials. Truth be told is that what has transpired over the past week is all really good news and I think investors are going to realize that very soon.

Check out all the filings. An 8k which is basically an employment agreement and 9 form 4s indicating insider buying.

It’s got to be awfully close. Trading at a tighter range today. If AMAG has gone up there is no reason why we shouldn’t follow.

Thank you.

I agree too that an injection is not optimal. That said, there is really no reason this should stay down. They have $60 million more than they had last week and an FDA approval that they stand to make another $300 million in milestone sales of the drug. They don’t have to pay any marketing costs. It’s just all profit and potential profit.

The stock was trading higher last week with none if this.

Probably not taking that into account but I don’t think it will effect pps long-term though imo.

A little dd...

1. During the May 9th conference call with investors, Stephen Wills, chief financial officer, said the company was "advancing discussions right now with multiple parties. Nothing is going to happen before the FDA's PDUFA date...”

2. Seems like a lot of criticism about Vyleesi but the fact remains that the FDA approved the drug. As a direct result Palatin gets a $60 mil payment from Amag. Critics doubt that Amag can sell the drug effectively, however, it is Amag who will be forking the bill for marketing the product while Palatin will collect royalties of up to $300 mil with the first royalty payment of $25 mil will be do once Amag reaches sales of $260 million. It is believed that the cost will be between $50 and $75 a dose. That said, at the very minimum Palatin gets $60 mil.

3. Palatin currently has 6 drugs in its pipeline. Vyleesi already has FDA approval while 2 others are in Phase 1 approval while 3 others are in clinical trials. Not a bad start.

4. Friday’s 8k stated that they could potentially dilute up to $40 mil. It was pretty obvious that that’s what they did today. With close to 55 mil volume today I would think that most of that was dilution which was obviously orchestrated. As a result, I would think that dilution should be close to be over

6. With the $40 dilution and the $60 mil coming to them they should have approximately $100 mil cash now. Market cap around $260 mil not counting the diluted shares.

With all of this it seems to me to be a nice set up for some positive price action.

I really doubt their intentions were to help ah. They put out the q because it’s what companies do. That said, the q seemed to be received as neutral. There was no sell-off nor was there buying. I wouldn’t be surprised though if we see a pr or an announcement of an earnings call.

That does seem to imply royalty payments are there. Interesting.

If your Exxon Mobil, $10 million is more like $100.

You could be right. I’ve only recently got into this stock. Looking at its previous share prices though and the lifeline that Exxon gave them it seems like there is some serious upside potential at these levels. No crystal ball but any elaboration on the deal or any positive news with this float and it could make a serious move.

I disagree as well. Canntrust is expecting a nice quarter and have had good earnings prior last earnings report. The share price has struggled for three reasons. First was the bad earnings report. That was followed by the $300 million offering. Then that was followed by the recent sector downturn.

That said, now they have $300 million cash. They are expecting a good quarter and production is ramping up. Next year by this time, I think the share price at the very least doubles. They are extremely under valued now

I will say this. The price action the last couple of days was very odd. With every bid the ask was right above it and it was stacked by different market makers. It was an obvious coordinated effort to keep the price down. The big question is why?

I guess the most logical choice would be a short attack but whoever was behind it had a lot had a lot of shares and stands to profit nicely from their efforts.

If it wasn’t a short attack then there are a couple of other scenarios. Dilution would be one but if it was dilution you tend to see more and bigger chunks of sales in to the bid. You don’t typically see the asks stacked like they were right above the bid.

Another possibility is that someone wanted to load shares cheap. If this was the case, that might explain the level 2 action but regardless it seemed like manipulation.

If he is giving you revenue numbers that would be illegal. I don’t think he a CEO would give revenue guidance numbers unless it was via a pr. I can believe it may be late though as I’ve seen it many times. The pink current status will disappear. That said I would expect a drop In pps until they file. Either way I do think once they file we should see a nice boost In pps.

We have a CEO! https://investors.charlottesweb.com/press-releases/press-release-details/2019/Charlottes-Web-Announces-Appointment-of-Deanie-Elsner-Former-Executive-Leader-at-Kellogg-and-Kraft-as-New-Chief-Executive-Officer/default.aspx

On the $cgc $acrgf deal. So Acreage shareholders get .5818 shares of Canopy plus $2.55 a share when deal goes through. So, If I own 500 shares of $acrgf at end of day today at $22.51 = $11,255. After deal, I would get .5818 shares of Canopy or roughly 291 shares at end of day today at $44.94 = $13,077.54 plus an additional $2.55 per share for $1275. Total = $14,352.54. So if the deal went through today an acreage shareholder of 500 shares would have a net profit of over $3,000 after the conversion. If $cgc goes higher then more $. Is this information correct? If so, I think acreage shareholders should make out well provided Canopy doesn’t tank in value.

Thank you. I didn’t see that.

Also my guess is that they intend to uplist in Canada to the TSX...

They specify $500,000,000 in common shares, not 500,000,000 shares. At least that’s how I read it. I would question that since this is filed in Canada, is this $500 mil Canadian dollars or $500 mil U.S. dollars? I’m assuming U.S. dollars since it was not otherwise specified.

Good point.